N/A N=66 "Laparoscopic" Cystoscopy Versus Traditional Cystoscopy
Lower Urinary Tract Injury
Primary: Time Required to Perform Procedure (in Seconds) — 137; 451 seconds
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
N/A N=36 Rigid Versus Flexible Cystoscopy in Women
Hematuria · Urination Disorders · Voiding Dysfunction
Primary: Visual Analog Scale for Pain — 1.8; 1.4 Units on a Scale — p=.39
Phase 3 N=304 A Study of Blue Light Flexible Cystoscopy With Cysview in the Detection of Bladder Cancer in the Surveillance Setting
Bladder Cancer
Primary: Proportion of Patients With Histologically Confirmed Malignancy Where Malignancy is Only Detected With Blue Light Cystoscopy With Cysview and Not White Light Cystoscopy…
N/A N=73 Real-world Evidence Study on Cystistat
Interstitial Cystitis and Bladder Pain Syndrome
Primary: Patient Global Assessment (PGA) — 90.1 percentage of participants (%)
N/A N=176 Evaluation of Ureteral Jets on Cystoscopy
Injury of Ureter
Primary: Ureteral Jet Visibility — 22; 35; 27; 41 Participants
N/A N=100 Trial Comparing Outpatient Flexible to Rigid Cystoscopy in Females
Pain
Primary: Post Procedural Complications, Including Frequency, Urgency, Infection and Time to Resolution of These Symptoms Between the Two Procedures. — 17; 15; 5; 15 participants
N/A N=122 Trendelenburg, Abdominal Insufflation and Time to Completion of Cystoscopy
Bladder Integrity · Bladder Function · Ureteral Integrity
Primary: Time in Seconds to Complete the Cystourethroscopy — 103; 117; 147; 82 seconds
Phase 3 N=158 Comparative Study of Hexvix Blue Light Cystoscopy and White Light Cystoscopy in the Detection of Bladder Cancer
Bladder Cancer
Primary: Number of Patients With Histology-confirmed Lesions (Ta, T1, or CIS) Who Have at Least One Such Lesion Found by Hexvix Blue Light Cystoscopy But Not by White Light…
N/A N=551 Longer-term Recurrence Rates in Patients With Bladder Cancer After Hexvix (Cysview)Fluorescence Cystoscopy/TURB
Bladder Cancer
Primary: Recurrence Free Survival — 9.6; 16.4 months — p=0.056
N/A N=60 Assessment of Infection Control, Practice Efficiency, and Health Economics of Sheathed Versus Standard Cystoscopy
Bacteriuria
Primary: Number of Participants Who Had Post-Procedure Bacteriuria — 0; 1 Participants
Phase 4 N=242 Cytoscopic Antibiotic Irrigant to Reduce Postoperative Urinary Tract Infection
Urinary Tract Infections
Primary: Urinary Tract Infection — 11; 12 UTI
N/A N=37 Evaluation of Sodium Fluorescein Use During Intraoperative Cystoscopy After Total Laparoscopic Hysterectomy
Ureteral Injury
Primary: Quality of Ureteral Efflux Coloration With Sodium Fluorescein Collected With Dedicated Questionnaire — 23; 4; 1; 1 Participants
Phase 3 N=233 A Randomized, Comparative Study of Hexvix Fluorescence Cystoscopy and Standard Cystoscopy in Patients With Non-invasive Bladder Cancer
Bladder Cancer
Primary: Proportion of Patients With Histologically Confirmed Recurrence Within One 1 Year. — 30.5; 47.3 precentage of participants — p=0.05
Phase 3 N=779 Study to Improve Detection and Early Recurrence Rate in Bladder Cancer Patients Using Hexvix Fluorescence Cystoscopy
Bladder Cancer
Primary: Proportion of Patients With >= 1 Ta or T1 Tumor Detected With Blue Light and Not White Light — 16.4 percentage of participants
Phase 4 N=130 Evaluation of Ureteral Patency in the Post-indigo Carmine Era
Ureteral Patency
Primary: Visual Analog Scale (VAS) — 48; 20; 0; 28 score on a scale
Phase 2 N=98 Efficacy and Safety Study of Uracyst to Treat Interstitial Cystitis/Painful Bladder Syndrome
Interstitial Cystitis · Painful Bladder Syndrome
Primary: Global Response Assessment (GRA) Responders at Week 11. — 19; 15 participants
N/A N=75 The Clinical Utility of Cholangioscopy and Pancreatoscopy in the Diagnosis and Management of Pancreaticobiliary Disorders
Disorders of the Pancreas and Biliary Tree
Primary: Successful Procedure Completion — 70; 5 participants
Phase 4 N=53 Intranasal Fentanyl as an Analgesic for Cystoscopic Procedures
Pain
Primary: Pre Procedure 0 - 10 Pain Numerical Rating Scale — 0; 0; 7; 5 0 - 10 Pain Numerical Rating Scale
Phase 2 N=77 S0219, Combination Chemotherapy Followed By Observation or Surgery in Patients With Stage II or Stage III Cancer of the Urothelium
Bladder Cancer · Transitional Cell Cancer of the Renal Pelvis and Ureter · Urethral Cancer
Primary: Pathologic Complete Response Rate by Transurethral Resection of Bladder Tumor (TURBT) and Imaging Studies After Chemotherapy — 46 percentage of participants
N/A N=107 Phenazopyridine for Confirmation of Ureteral Patency
Cystoscopy
Primary: Time to Visualize Ureteral Urine Flow Intraoperatively Measured by Timing in the Operating Room — 160; 173 seconds — p=0.77
Phase 2 N=28 Bristol Bladder Trial
Infiltrating Bladder Urothelial Carcinoma
Primary: Overall Pathological Response Rate — 57.7 % of participants
N/A N=102 Relationship Between Bladder Distention and Hysteroscopy Application
Menorrhagia
Primary: Ease of Cervical Entry — 4.00; 3.55 units on a scale
N/A N=199 Patient Satisfaction Study: Clean Intermittent Self-Catheterization Teaching
Anxiety
Primary: State-Trait Anxiety Inventory-State Scores — 37.9; 40.7; NA; 37.7 units on a scale
N/A N=95 Impact Ureteral Sheath Design During Ureteroscopy
Renal Stone · Nephrolithiasis · Urolithiasis
Primary: Number of Participants With Successful Sheath Placement — 37; 39 Participants
N/A N=350 Open Vs Robotic-Assisted Radical Cystectomy: A Randomized Trial
Bladder Cancer Requiring Cystectomy
Primary: Percentage of Participants With 2-year Progression Free Survival (PFS) — 71.6; 72.3 percentage of participants
Phase 3 N=82 The Bladder Instillation Comparison Study
Urinary Bladder Neoplasms
Primary: Number of Participants Without Grade ≥ 3 Adverse Event, Graded According to NCI CTCAE Version 4.03 — 15; 14; 20 Participants
N/A N=30 CLinical Evaluation of Aspiration for Removal ANd ClearancE of Stones
Renal Stones · Kidney Stone · Urolithiasis
Primary: Stone Clearance (% Reduction in Stone Volume) — 96.2 % stone volume removed
N/A N=53 URACYST® For the Treatment of GAG Deficient Interstitial Cystitis
Painful Bladder Syndrome · Interstitial Cystitis
Primary: Percentage of Responders to Treatment — 25 Participants
N/A N=88 Clinical Utility of ERCP Guided Cholangiopancreatoscopy With the SpyGlass DS
Biliary Tract Disease
Primary: Number of Participants With Procedure Technical Success — 70; 3 participants
N/A N=300 Cefpodoxime vs Ciprofloxacin for Acute Cystitis
Urinary Tract Infection
Primary: Clinical Cure — 140; 123; 10; 27 participants